$MDT
Medtronic plc Stock $mdt

$mdt Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-K Financial Statement

#000161310319000028 Filed on June 21, 2019

Income Statement

Concept	2019 Q2	2018 Q2	2018 Q1
Revenue	$8.146B	$8.144B	$7.369B
YoY Change	0.02%	2.88%	1.18%
Cost Of Revenue	$2.450B	$2.383B	$2.194B
YoY Change	2.81%	-1.93%	-3.26%
Gross Profit	$5.663B	$5.746B	$5.175B
YoY Change	-1.44%	4.85%	3.19%
Gross Profit Margin	69.52%	70.56%	70.23%
Selling, General & Admin	$2.640B	$2.533B	$2.523B
YoY Change	4.22%	-9.08%	5.65%
% of Gross Profit	46.62%	44.08%	48.75%
Research & Development	$594.0M	$592.0M	$559.0M
YoY Change	0.34%	7.05%	5.47%
% of Gross Profit	10.49%	10.3%	10.8%
Depreciation & Amortization	$667.0M	$664.0M	$666.0M
YoY Change	0.45%	-7.52%	-8.77%
% of Gross Profit	11.78%	11.56%	12.87%
Operating Expenses	$3.488B	$3.719B	$3.082B
YoY Change	-6.21%	-2.97%	5.62%
Operating Profit	$2.175B	$2.027B	$1.436B
YoY Change	7.3%	23.07%	25.2%
Interest Expense	-$99.00M	-$345.0M	$270.0M
YoY Change	-71.3%	200.0%	0.75%
% of Operating Profit	-4.55%	-17.02%	18.8%
Other Income/Expense, Net	-$17.00M	$234.0M	-$140.0M
YoY Change	-107.26%	-541.51%	204.35%
Pretax Income	$1.292B	$1.725B	$1.027B
YoY Change	-25.1%	20.21%	6.2%
Income Tax	$115.0M	$223.0M	$2.419B
% Of Pretax Income	8.9%	12.93%	235.54%
Net Earnings	$1.172B	$1.460B	-$1.389B
YoY Change	-19.73%	25.54%	-269.18%
Net Earnings / Revenue	14.39%	17.93%	-18.85%
Basic Earnings Per Share	$0.87	$1.08	-$1.03
Diluted Earnings Per Share	$0.87	$1.07	-$1.03
COMMON SHARES
Basic Shares Outstanding	1.341B shares	1.352B shares	1.354B shares
Diluted Shares Outstanding			1.354B shares

Balance Sheet

Concept	2019 Q2	2018 Q2	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.848B	$11.23B	$14.44B
YoY Change	-12.28%	-18.1%	25.99%
Cash & Equivalents	$4.393B	$3.669B	$6.358B
Short-Term Investments	$5.455B	$7.558B	$8.078B
Other Short-Term Assets	$2.144B	$2.187B	$2.645B
YoY Change	-1.97%	17.27%	47.6%
Inventory	$3.753B	$3.579B	$3.751B
Prepaid Expenses
Receivables	$6.222B	$5.987B	$5.775B
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$21.97B	$22.98B	$26.61B
YoY Change	-4.41%	-7.61%	18.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.675B	$4.604B	$4.517B
YoY Change	1.54%	5.57%	-8.69%
Goodwill	$39.96B	$39.54B	$39.80B
YoY Change	1.05%	2.67%	-3.47%
Intangibles	$20.56B	$21.72B	$22.18B
YoY Change	-5.35%	-7.19%	-15.38%
Long-Term Investments	$372.0M	$18.00M	$600.0M
YoY Change	1966.67%
Other Assets	$1.014B	$1.078B	$1.166B
YoY Change	-5.94%	-12.5%	-9.68%
Total Long-Term Assets	$67.73B	$68.41B	$69.19B
YoY Change	-1.0%	-8.76%	-7.93%
TOTAL ASSETS
Total Short-Term Assets	$21.97B	$22.98B	$26.61B
Total Long-Term Assets	$67.73B	$68.41B	$69.19B
Total Assets	$89.69B	$91.39B	$95.80B
YoY Change	-1.86%	-8.48%	-1.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.953B	$1.628B	$1.809B
YoY Change	19.96%	4.69%	16.18%
Accrued Expenses	$4.885B	$5.232B	$4.975B
YoY Change	-6.63%	17.76%	24.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$838.0M	$2.058B	$2.902B
YoY Change	-59.28%	-72.54%	-53.39%
Total Short-Term Liabilities	$8.472B	$10.08B	$10.93B
YoY Change	-15.99%	-29.3%	-13.72%
LONG-TERM LIABILITIES
Long-Term Debt	$24.55B	$23.69B	$25.92B
YoY Change	3.63%	-8.43%	-0.02%
Other Long-Term Liabilities	$757.0M	$889.0M	$964.0M
YoY Change	-14.85%	-41.32%	-43.63%
Total Long-Term Liabilities	$25.31B	$24.58B	$964.0M
YoY Change	2.96%	-10.25%	-43.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.472B	$10.08B	$10.93B
Total Long-Term Liabilities	$25.31B	$24.58B	$964.0M
Total Liabilities	$39.48B	$40.57B	$45.46B
YoY Change	-2.68%	-18.08%	-5.46%
SHAREHOLDERS EQUITY
Retained Earnings	$26.27B	$24.38B	$23.43B
YoY Change	7.76%	4.77%	-55.18%
Common Stock	$0.00	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$50.09B	$50.72B	$50.23B
YoY Change
Total Liabilities & Shareholders Equity	$89.69B	$91.39B	$95.80B
YoY Change	-1.86%	-8.48%	-1.82%

Cashflow Statement

Concept	2019 Q2	2018 Q2	2018 Q1
OPERATING ACTIVITIES
Net Income	$1.172B	$1.460B	-$1.389B
YoY Change	-19.73%	25.54%	-269.18%
Depreciation, Depletion And Amortization	$667.0M	$664.0M	$666.0M
YoY Change	0.45%	-7.52%	-8.77%
Cash From Operating Activities	$2.087B	$1.038B	$2.002B
YoY Change	101.06%	-41.46%	-3.98%
INVESTING ACTIVITIES
Capital Expenditures	-$335.0M	-$292.0M	-$252.0M
YoY Change	14.73%	-11.52%	-22.7%
Acquisitions
YoY Change
Other Investing Activities	-$194.0M	$403.0M	-$126.0M
YoY Change	-148.14%	594.83%	-79.55%
Cash From Investing Activities	-$529.0M	$111.0M	-$378.0M
YoY Change	-576.58%	-140.81%	-59.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-860.0M	-3.828B	-849.0M
YoY Change	-77.53%	-657.21%	-35.63%
NET CHANGE
Cash From Operating Activities	2.087B	1.038B	2.002B
Cash From Investing Activities	-529.0M	111.0M	-378.0M
Cash From Financing Activities	-860.0M	-3.828B	-849.0M
Net Change In Cash	698.0M	-2.679B	775.0M
YoY Change	-126.05%	-222.44%	-540.34%
FREE CASH FLOW
Cash From Operating Activities	$2.087B	$1.038B	$2.002B
Capital Expenditures	-$335.0M	-$292.0M	-$252.0M
Free Cash Flow	$2.422B	$1.330B	$2.254B
YoY Change	82.11%	-36.76%	-6.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-26
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-04-26
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001613103
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019	dei	Entity Registrant Name EntityRegistrantName	Medtronic plc
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019Q2	mdt	Deferred Stock Shares Outstanding DeferredStockSharesOutstanding	0	shares
CY2019	mdt	Defined Contribution Plan Treasury Bond Rate Of Guaranteed Rate Of Return DefinedContributionPlanTreasuryBondRateOfGuaranteedRateOfReturn	P10Y
CY2017	mdt	Dispositionof Business Related Expenses DispositionofBusinessRelatedExpenses	0	USD
CY2017	mdt	Gain Lossfrom Hedged Firm Commitment Not Qualifyingas Net Investment Hedge Net GainLossfromHedgedFirmCommitmentNotQualifyingasNetInvestmentHedgeNet	0	USD
CY2018	mdt	Gain Lossfrom Hedged Firm Commitment Not Qualifyingas Net Investment Hedge Net GainLossfromHedgedFirmCommitmentNotQualifyingasNetInvestmentHedgeNet	0	USD
CY2018Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	193000000	USD
CY2019Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	190000000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1800000000	USD
CY2017	us-gaap	Amount Of Ineffectiveness On Net Investment Hedges AmountOfIneffectivenessOnNetInvestmentHedges	0	USD
CY2018	us-gaap	Amount Of Ineffectiveness On Net Investment Hedges AmountOfIneffectivenessOnNetInvestmentHedges	0	USD
CY2017	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.72
CY2018	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.84
CY2019	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	2.00
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2600000000	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1354218154	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1340697595	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1354218154	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1340697595	shares
CY2017	us-gaap	Gain Loss From Hedged Firm Commitment Not Qualifying As Fair Value Hedge Net GainLossFromHedgedFirmCommitmentNotQualifyingAsFairValueHedgeNet	0	USD
CY2018	us-gaap	Gain Loss From Hedged Firm Commitment Not Qualifying As Fair Value Hedge Net GainLossFromHedgedFirmCommitmentNotQualifyingAsFairValueHedgeNet	0	USD
CY2017	us-gaap	Gain Loss On Foreign Currency Cash Flow Hedge Ineffectiveness GainLossOnForeignCurrencyCashFlowHedgeIneffectiveness	0	USD
CY2018	us-gaap	Gain Loss On Foreign Currency Cash Flow Hedge Ineffectiveness GainLossOnForeignCurrencyCashFlowHedgeIneffectiveness	0	USD
CY2017	us-gaap	Gain Loss On Interest Rate Fair Value Hedge Ineffectiveness GainLossOnInterestRateFairValueHedgeIneffectiveness	0	USD
CY2018	us-gaap	Gain Loss On Interest Rate Fair Value Hedge Ineffectiveness GainLossOnInterestRateFairValueHedgeIneffectiveness	0	USD
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018Q2	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0	USD
CY2018	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Reductions Securities Sold OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsReductionsSecuritiesSold	0	USD
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018Q4	dei	Entity Public Float EntityPublicFloat	120800000000	USD
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1341156703	shares
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30557000000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29953000000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29710000000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9155000000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9067000000	USD
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9294000000	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2330000000	USD
CY2018	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2256000000	USD
CY2017	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2193000000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10418000000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10238000000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10018000000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1764000000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1823000000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1980000000	USD
CY2019	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	198000000	USD
CY2018	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	30000000	USD
CY2017	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	303000000	USD
CY2019	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	166000000	USD
CY2018	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	61000000	USD
CY2017	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	300000000	USD
CY2019	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2018	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	697000000	USD
CY2017	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2019	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-258000000	USD
CY2018	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-535000000	USD
CY2017	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-239000000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	6268000000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	6640000000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	5383000000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	373000000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	181000000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	313000000	USD
CY2019	us-gaap	Interest Expense InterestExpense	1444000000	USD
CY2018	us-gaap	Interest Expense InterestExpense	1146000000	USD
CY2017	us-gaap	Interest Expense InterestExpense	1094000000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5197000000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5675000000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	4602000000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	547000000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2580000000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	578000000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	4650000000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	3095000000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	4024000000	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	19000000	USD
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9000000	USD
CY2017	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	4631000000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	3104000000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	4028000000	USD
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.44
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.29
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.92
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.41
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.27
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.89
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1346400000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1356700000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1378900000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1357500000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1368200000	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1391400000	shares
CY2019	us-gaap	Profit Loss ProfitLoss	4650000000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	3095000000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	4024000000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	102000000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-103000000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	38000000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1375000000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1184000000	USD
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-977000000	USD
CY2019	mdt	Other Comprehensive Income Loss Unrealized Gain Loss On Derivatives Arising During Period Net Investment Hedge Net Of Tax OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax	88000000	USD
CY2018	mdt	Other Comprehensive Income Loss Unrealized Gain Loss On Derivatives Arising During Period Net Investment Hedge Net Of Tax OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax	0	USD
CY2017	mdt	Other Comprehensive Income Loss Unrealized Gain Loss On Derivatives Arising During Period Net Investment Hedge Net Of Tax OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax	0	USD
CY2019	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	191000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-167000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-68000000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	401000000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-218000000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	127000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-975000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1030000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-744000000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	3675000000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	4125000000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	3280000000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	16000000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-9000000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-3000000	USD
CY2019Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	24486000000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3659000000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4134000000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3283000000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4393000000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3669000000	USD
CY2019Q2	us-gaap	Short Term Investments ShortTermInvestments	5455000000	USD
CY2018Q2	us-gaap	Short Term Investments ShortTermInvestments	7558000000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6222000000	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5987000000	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	3753000000	USD
CY2018Q2	us-gaap	Inventory Net InventoryNet	3579000000	USD
CY2019Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2144000000	USD
CY2018Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2187000000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	21967000000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	22980000000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4675000000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4604000000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	39959000000	USD
CY2018Q2	us-gaap	Goodwill Goodwill	39543000000	USD
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20560000000	USD
CY2018Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	21723000000	USD
CY2019Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1519000000	USD
CY2018Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1465000000	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1014000000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1078000000	USD
CY2019Q2	us-gaap	Assets Assets	89694000000	USD
CY2018Q2	us-gaap	Assets Assets	91393000000	USD
CY2019Q2	us-gaap	Debt Current DebtCurrent	838000000	USD
CY2018Q2	us-gaap	Debt Current DebtCurrent	2058000000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1953000000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1628000000	USD
CY2019Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	2189000000	USD
CY2018Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1988000000	USD
CY2019Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	567000000	USD
CY2018Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	979000000	USD
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2925000000	USD
CY2018Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3431000000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8472000000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10084000000	USD
CY2018Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	23699000000	USD
CY2019Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1651000000	USD
CY2018Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1425000000	USD
CY2019Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	2838000000	USD
CY2018Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	3051000000	USD
CY2019Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1278000000	USD
CY2018Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1423000000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	757000000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	889000000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	39482000000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	40571000000	USD
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2019Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26532000000	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	28127000000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	26270000000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	24379000000	USD
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2711000000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1786000000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	50091000000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	50720000000	USD
CY2019Q2	us-gaap	Minority Interest MinorityInterest	121000000	USD
CY2018Q2	us-gaap	Minority Interest MinorityInterest	102000000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50212000000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50822000000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89694000000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91393000000	USD
CY2016Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	51977000000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	4024000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-744000000	USD
CY2017	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	2376000000	USD
CY2017	mdt	Stock Issued During Period Value Share Based Compensation8 StockIssuedDuringPeriodValueShareBasedCompensation8	428000000	USD
CY2017	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	3544000000	USD
CY2017	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	92000000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	348000000	USD
CY2017	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	125000000	USD
CY2017Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50330000000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	3095000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1030000000	USD
CY2018	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	2494000000	USD
CY2018	mdt	Stock Issued During Period Value Share Based Compensation8 StockIssuedDuringPeriodValueShareBasedCompensation8	329000000	USD
CY2018	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	2097000000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	344000000	USD
CY2018	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-11000000	USD
CY2017Q2	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	296000000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50822000000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	4650000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-975000000	USD
CY2019	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	2693000000	USD
CY2019	mdt	Stock Issued During Period Value Share Based Compensation8 StockIssuedDuringPeriodValueShareBasedCompensation8	923000000	USD
CY2019	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	2808000000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	290000000	USD
CY2019	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	3000000	USD
CY2018Q2	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50212000000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	4650000000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	3095000000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	4024000000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2659000000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2644000000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2917000000	USD
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	78000000	USD
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	52000000	USD
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	39000000	USD
CY2019	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-304000000	USD
CY2018	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-919000000	USD
CY2017	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-459000000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	290000000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	344000000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	348000000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-457000000	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-38000000	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2018	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	697000000	USD
CY2017	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2019	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2018	us-gaap	Impairment Of Investments ImpairmentOfInvestments	227000000	USD
CY2017	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-257000000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-73000000	USD
CY2017	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	128000000	USD
CY2019	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	581000000	USD
CY2018	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	275000000	USD
CY2017	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	75000000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	274000000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	192000000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	399000000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	227000000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	65000000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	356000000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	624000000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-229000000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-85000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7007000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4684000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6880000000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1827000000	USD
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	137000000	USD
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1324000000	USD
CY2019	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2018	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	6058000000	USD
CY2017	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1134000000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1068000000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1254000000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2532000000	USD
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	3200000000	USD
CY2017	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	4371000000	USD
CY2019	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	4683000000	USD
CY2018	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	4227000000	USD
CY2017	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	5356000000	USD
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-36000000	USD
CY2018	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	22000000	USD
CY2017	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-22000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-774000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5858000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1571000000	USD
CY2019	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	-713000000	USD
CY2018	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	-249000000	USD
CY2017	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	906000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	7794000000	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	21000000	USD
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2140000000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	7948000000	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	7370000000	USD
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	863000000	USD
CY2019	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	2693000000	USD
CY2018	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	2494000000	USD
CY2017	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	2376000000	USD
CY2019	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	992000000	USD
CY2018	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	403000000	USD
CY2017	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	428000000	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2877000000	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2171000000	USD
CY2017	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3544000000	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	14000000	USD
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-94000000	USD
CY2017	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	26000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5431000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11954000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3283000000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-78000000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	114000000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65000000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	724000000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1298000000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2091000000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3669000000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4967000000	USD
CY2016Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2876000000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4393000000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3669000000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4967000000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1558000000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2542000000	USD
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1029000000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	973000000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	1147000000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	1134000000	USD
CY2019	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. For the purpose of providing more concise consolidated statements of income, amounts previously reported in <span style="font-family:inherit;font-size:10pt;font-style:italic;">acquisition-related items</span><span style="font-family:inherit;font-size:10pt;"> were reclassified to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">selling, general, and administrative expense</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">other operating expense, net</span><span style="font-family:inherit;font-size:10pt;">; amounts previously reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">divestiture-related items</span><span style="font-family:inherit;font-size:10pt;"> were reclassified to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">selling, general, and administrative expense</span><span style="font-family:inherit;font-size:10pt;">; amounts previously reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">special charge</span><span style="font-family:inherit;font-size:10pt;"> were reclassified to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">other operating expense, net</span><span style="font-family:inherit;font-size:10pt;">, and amounts previously reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">investment loss</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">interest income</span><span style="font-family:inherit;font-size:10pt;"> were reclassified to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">other non-operating income, net.</span><span style="font-family:inherit;font-size:10pt;"> </span>
CY2019	us-gaap	Use Of Estimates UseOfEstimates	The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used when accounting for items such as income taxes, contingencies, intangible asset, and liability valuations. Actual results may or may not differ from those estimates.
CY2019	us-gaap	Fiscal Period FiscalPeriod	The Company utilizes a 52/53-week fiscal year, ending the last Friday in April, for the presentation of its consolidated financial statements and related notes thereto at <span style="font-family:inherit;font-size:10pt;">April 26, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">April 27, 2018</span><span style="font-family:inherit;font-size:10pt;"> and for each of the three fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">April 26, 2019</span><span style="font-family:inherit;font-size:10pt;"> (fiscal year </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">), </span><span style="font-family:inherit;font-size:10pt;">April 27, 2018</span><span style="font-family:inherit;font-size:10pt;"> (fiscal year </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">), and </span><span style="font-family:inherit;font-size:10pt;">April 28, 2017</span><span style="font-family:inherit;font-size:10pt;"> (fiscal year </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">). Fiscal years </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were 52-week years. </span>
CY2018	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	-34000000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30557000000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29953000000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29710000000	USD
CY2019Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	315000000	USD
CY2018Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	289000000	USD
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	199000000	USD
CY2019Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	900000000	USD
CY2019Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P4Y
CY2019Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	222000000	USD
CY2018Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	173000000	USD
CY2018Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	173000000	USD
CY2017Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	246000000	USD
CY2019	mdt	Business Acquisition Purchase Price Contingent Consideration BusinessAcquisitionPurchasePriceContingentConsideration	151000000	USD
CY2018	mdt	Business Acquisition Purchase Price Contingent Consideration BusinessAcquisitionPurchasePriceContingentConsideration	28000000	USD
CY2019	mdt	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	36000000	USD
CY2018	mdt	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	72000000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	66000000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	29000000	USD
CY2019Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	222000000	USD
CY2018Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	173000000	USD
CY2019	mdt	Restructuring Charges Netof Accrual Adjustments RestructuringChargesNetofAccrualAdjustments	407000000	USD
CY2019	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	-17000000	USD
CY2018	mdt	Restructuring Charges Netof Accrual Adjustments RestructuringChargesNetofAccrualAdjustments	107000000	USD
CY2019Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-29000000	USD
CY2018Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-120000000	USD
CY2019Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	104000000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	5540000000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	20000000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	61000000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	5499000000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	6963000000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	22000000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	165000000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	6820000000	USD
CY2019Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	1075000000	USD
CY2019Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	9000000	USD
CY2019Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	2181000000	USD
CY2019Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	52000000	USD
CY2018Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	4094000000	USD
CY2018Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	107000000	USD
CY2018Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	891000000	USD
CY2018Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	58000000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	3718000000	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	3309000000	USD
CY2017	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	3646000000	USD
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	18000000	USD
CY2018	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	27000000	USD
CY2017	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	49000000	USD
CY2019	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	62000000	USD
CY2018	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	21000000	USD
CY2017	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	14000000	USD
CY2019Q2	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0	USD
CY2019	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Reductions Securities Sold OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsReductionsSecuritiesSold	0	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1022000000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	2198000000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	2244000000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	35000000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	5499000000	USD
CY2018Q2	mdt	Costand Equity Method Investments Carrying Value Before Realized Loss CostandEquityMethodInvestmentsCarryingValueBeforeRealizedLoss	317000000	USD
CY2019Q2	us-gaap	Debt Current DebtCurrent	838000000	USD
CY2018Q2	us-gaap	Debt Current DebtCurrent	2058000000	USD
CY2018Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	107000000	USD
CY2019Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	24486000000	USD
CY2018Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	23699000000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	838000000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2747000000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	3258000000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2862000000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	1161000000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	14524000000	USD
CY2019Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	25390000000	USD
CY2019Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	838000000	USD
CY2019Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	24552000000	USD
CY2019Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	26200000000	USD
CY2019Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	25000000000.0	USD
CY2018Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	25100000000	USD
CY2018Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	24500000000	USD
CY2019	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	236000000	USD
CY2018	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-226000000	USD
CY2017	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	54000000	USD
CY2019	us-gaap	Gain Loss On Foreign Currency Cash Flow Hedge Ineffectiveness GainLossOnForeignCurrencyCashFlowHedgeIneffectiveness	0	USD
CY2017	us-gaap	Gain Loss On Interest Rate Cash Flow Hedge Ineffectiveness GainLossOnInterestRateCashFlowHedgeIneffectiveness	0	USD
CY2019Q2	mdt	Unrealized Gain Loss On Interest Rate Cash Flow Hedges Accumulated Other Comprehensive Income Loss Net Of Tax UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax	194000000	USD
CY2018Q2	mdt	Unrealized Gain Loss On Interest Rate Cash Flow Hedges Accumulated Other Comprehensive Income Loss Net Of Tax UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax	-207000000	USD
CY2019	us-gaap	Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths	175000000	USD
CY2019	mdt	Unrealized Gain Losson Net Investment Hedges Accumulated Other Comprehensive Income Loss Netof Tax UnrealizedGainLossonNetInvestmentHedgesAccumulatedOtherComprehensiveIncomeLossNetofTax	-169000000	USD
CY2018	mdt	Unrealized Gain Losson Net Investment Hedges Accumulated Other Comprehensive Income Loss Netof Tax UnrealizedGainLossonNetInvestmentHedgesAccumulatedOtherComprehensiveIncomeLossNetofTax	-257000000	USD
CY2019	mdt	Net Investment Hedge Gain Losstobe Reclassified Within Twelve Months NetInvestmentHedgeGainLosstobeReclassifiedWithinTwelveMonths	0	USD
CY2019	us-gaap	Amount Of Ineffectiveness On Net Investment Hedges AmountOfIneffectivenessOnNetInvestmentHedges	0	USD
CY2019	mdt	Gain Lossfrom Hedged Firm Commitment Not Qualifyingas Net Investment Hedge Net GainLossfromHedgedFirmCommitmentNotQualifyingasNetInvestmentHedgeNet	0	USD
CY2019	us-gaap	Gain Loss On Interest Rate Fair Value Hedge Ineffectiveness GainLossOnInterestRateFairValueHedgeIneffectiveness	0	USD
CY2019	us-gaap	Gain Loss From Hedged Firm Commitment Not Qualifying As Fair Value Hedge Net GainLossFromHedgedFirmCommitmentNotQualifyingAsFairValueHedgeNet	0	USD
CY2019Q2	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	365000000	USD
CY2019Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	19000000	USD
CY2018Q2	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	118000000	USD
CY2018Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	258000000	USD
CY2019Q2	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	365000000	USD
CY2019Q2	us-gaap	Derivative Asset Not Offset Policy Election Deduction DerivativeAssetNotOffsetPolicyElectionDeduction	9000000	USD
CY2019Q2	us-gaap	Derivative Collateral Obligation To Return Cash DerivativeCollateralObligationToReturnCash	44000000	USD
CY2019Q2	us-gaap	Derivative Collateral Obligation To Return Securities DerivativeCollateralObligationToReturnSecurities	0	USD
CY2019Q2	us-gaap	Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral	312000000	USD
CY2019Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	19000000	USD
CY2019Q2	us-gaap	Derivative Liability Not Offset Policy Election Deduction DerivativeLiabilityNotOffsetPolicyElectionDeduction	9000000	USD
CY2019Q2	us-gaap	Derivative Collateral Right To Reclaim Cash DerivativeCollateralRightToReclaimCash	0	USD
CY2019Q2	us-gaap	Derivative Collateral Right To Reclaim Securities DerivativeCollateralRightToReclaimSecurities	0	USD
CY2019Q2	us-gaap	Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral	10000000	USD
CY2019Q2	mdt	Derivative Asset Liability Fair Value Gross Asset Liability DerivativeAssetLiabilityFairValueGrossAssetLiability	346000000	USD
CY2019Q2	mdt	Derivative Assetsand Liabilities Net Not Offset Policy Election Deduction DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction	0	USD
CY2019Q2	mdt	Derivative Assetsand Liabilities Net Collateral Obligationto Return Cash DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash	44000000	USD
CY2019Q2	mdt	Derivative Assets And Liabilities Net Collateral Rightto Reclaim Securities DerivativeAssetsAndLiabilitiesNetCollateralRighttoReclaimSecurities	0	USD
CY2019Q2	us-gaap	Derivative Fair Value Amount Offset Against Collateral Net DerivativeFairValueAmountOffsetAgainstCollateralNet	302000000	USD
CY2018Q2	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	118000000	USD
CY2018Q2	us-gaap	Derivative Asset Not Offset Policy Election Deduction DerivativeAssetNotOffsetPolicyElectionDeduction	71000000	USD
CY2018Q2	us-gaap	Derivative Collateral Obligation To Return Cash DerivativeCollateralObligationToReturnCash	0	USD
CY2018Q2	us-gaap	Derivative Collateral Obligation To Return Securities DerivativeCollateralObligationToReturnSecurities	0	USD
CY2018Q2	us-gaap	Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral	47000000	USD
CY2018Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	258000000	USD
CY2018Q2	us-gaap	Derivative Liability Not Offset Policy Election Deduction DerivativeLiabilityNotOffsetPolicyElectionDeduction	71000000	USD
CY2018Q2	us-gaap	Derivative Collateral Right To Reclaim Cash DerivativeCollateralRightToReclaimCash	0	USD
CY2018Q2	us-gaap	Derivative Collateral Right To Reclaim Securities DerivativeCollateralRightToReclaimSecurities	76000000	USD
CY2018Q2	us-gaap	Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral	111000000	USD
CY2018Q2	mdt	Derivative Asset Liability Fair Value Gross Asset Liability DerivativeAssetLiabilityFairValueGrossAssetLiability	-140000000	USD
CY2018Q2	mdt	Derivative Assetsand Liabilities Net Not Offset Policy Election Deduction DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction	0	USD
CY2018Q2	mdt	Derivative Assetsand Liabilities Net Collateral Obligationto Return Cash DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash	0	USD
CY2018Q2	mdt	Derivative Assets And Liabilities Net Collateral Rightto Reclaim Securities DerivativeAssetsAndLiabilitiesNetCollateralRighttoReclaimSecurities	-76000000	USD
CY2018Q2	us-gaap	Derivative Fair Value Amount Offset Against Collateral Net DerivativeFairValueAmountOffsetAgainstCollateralNet	-64000000	USD
CY2019Q2	mdt	Derivative Assetsand Liabilities Net Collateral Obligationto Return Cash DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash	44000000	USD
CY2018Q2	mdt	Derivative Assets And Liabilities Net Collateral Rightto Reclaim Securities DerivativeAssetsAndLiabilitiesNetCollateralRighttoReclaimSecurities	-76000000	USD
CY2019Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2476000000	USD
CY2018Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2407000000	USD
CY2019Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	572000000	USD
CY2018Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	496000000	USD
CY2019Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	705000000	USD
CY2018Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	676000000	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	3753000000	USD
CY2018Q2	us-gaap	Inventory Net InventoryNet	3579000000	USD
CY2017Q2	us-gaap	Goodwill Goodwill	38515000000	USD
CY2018	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	52000000	USD
CY2018	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	54000000	USD
CY2018	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	922000000	USD
CY2018Q2	us-gaap	Goodwill Goodwill	39543000000	USD
CY2019	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	1510000000	USD
CY2019	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-1094000000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	39959000000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29004000000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9048000000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29434000000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8201000000	USD
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	87000000	USD
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	30000000	USD
CY2018	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	68000000	USD
CY2017	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1800000000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000000.0	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1741000000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1724000000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1684000000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1615000000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1574000000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4604000000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10920000000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10259000000	USD
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6245000000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5655000000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4675000000	USD
CY2019	us-gaap	Depreciation Depreciation	895000000	USD
CY2018	us-gaap	Depreciation Depreciation	821000000	USD
CY2017	us-gaap	Depreciation Depreciation	937000000	USD
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2600000000	shares
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q2	mdt	Deferred Stock Shares Authorized DeferredStockSharesAuthorized	40000	shares
CY2019Q2	mdt	Deferred Stock Paror Stated Value Per Share DeferredStockParorStatedValuePerShare	1.00
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	127500000	shares
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.20
CY2019Q2	mdt	Deferred Stock Shares Authorized DeferredStockSharesAuthorized	40000	shares
CY2019Q2	mdt	Deferred Stock Paror Stated Value Per Share DeferredStockParorStatedValuePerShare	1.00
CY2019Q2	mdt	Deferred Stock Shares Issued DeferredStockSharesIssued	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	127500000	shares
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.20
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.77
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.71
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.70
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M28D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M4D
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0290
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0200
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0126
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.1777
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.1951
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2107
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0225
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0219
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0197
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	290000000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	344000000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	348000000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	290000000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	344000000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	348000000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	54000000	USD
CY2018	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	82000000	USD
CY2017	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	98000000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	236000000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	262000000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	250000000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	877000000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-958000000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-234000000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	4320000000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	6633000000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	4836000000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5197000000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5675000000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	4602000000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	579000000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2899000000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	614000000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	406000000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	796000000	USD
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	840000000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	985000000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3695000000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1454000000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-310000000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	45000000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-399000000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-128000000	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1160000000	USD
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-477000000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-438000000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1115000000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-876000000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	547000000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2580000000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	578000000	USD
CY2019	us-gaap	Tax Cuts And Jobs Act Of2017 Income Tax Expense Benefit TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit	2400000000	USD
CY2019	us-gaap	Tax Cuts And Jobs Act Of2017 Income Tax Expense Benefit TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit	2400000000	USD
CY2019	mdt	Tax Cuts And Jobs Act Of2017 Transition Tax For Accumulated Foreign Earnings Income Tax Expense Benefit TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit	2400000000	USD
CY2019	mdt	Tax Cutsand Jobs Actof2017 Undistributed Accumulated Earningsof Foreign Subsidiary Income Tax Expense Benefit TaxCutsandJobsActof2017UndistributedAccumulatedEarningsofForeignSubsidiaryIncomeTaxExpenseBenefit	118000000	USD
CY2019	us-gaap	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit	75000000	USD
CY2019Q2	mdt	Deferred Tax Assets Operating And Capital Losses And Tax Credit Carryforwards DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards	6574000000	USD
CY2018Q2	mdt	Deferred Tax Assets Operating And Capital Losses And Tax Credit Carryforwards DeferredTaxAssetsOperatingAndCapitalLossesAndTaxCreditCarryforwards	7463000000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	389000000	USD
CY2018Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	410000000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	315000000	USD
CY2018Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	209000000	USD
CY2019Q2	mdt	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits And Pensions DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions	300000000	USD
CY2018Q2	mdt	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits And Pensions DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefitsAndPensions	256000000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	162000000	USD
CY2018Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	190000000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	339000000	USD
CY2018Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	332000000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	194000000	USD
CY2018Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	207000000	USD
CY2019Q2	mdt	Deferred Tax Assets Tax Deferred Expense Federal And State Benefit On Uncertain Tax Positions DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions	83000000	USD
CY2018Q2	mdt	Deferred Tax Assets Tax Deferred Expense Federal And State Benefit On Uncertain Tax Positions DeferredTaxAssetsTaxDeferredExpenseFederalAndStateBenefitOnUncertainTaxPositions	67000000	USD
CY2019Q2	mdt	Deferred Tax Assets Interest Limitation DeferredTaxAssetsInterestLimitation	111000000	USD
CY2018Q2	mdt	Deferred Tax Assets Interest Limitation DeferredTaxAssetsInterestLimitation	0	USD
CY2019Q2	mdt	Deferred Tax Assets Unrealized Losses On Available For Sale Securities And Derivative Financial Instruments DeferredTaxAssetsUnrealizedLossesOnAvailableForSaleSecuritiesAndDerivativeFinancialInstruments	17000000	USD
CY2018Q2	mdt	Deferred Tax Assets Unrealized Losses On Available For Sale Securities And Derivative Financial Instruments DeferredTaxAssetsUnrealizedLossesOnAvailableForSaleSecuritiesAndDerivativeFinancialInstruments	93000000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8484000000	USD
CY2018Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9227000000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6300000000	USD
CY2018Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7166000000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2184000000	USD
CY2018Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2061000000	USD
CY2019Q2	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1614000000	USD
CY2018Q2	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1697000000	USD
CY2019Q2	us-gaap	Deferred Tax Liabilities Derivatives DeferredTaxLiabilitiesDerivatives	70000000	USD
CY2018Q2	us-gaap	Deferred Tax Liabilities Derivatives DeferredTaxLiabilitiesDerivatives	69000000	USD
CY2019Q2	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	152000000	USD
CY2018Q2	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	143000000	USD
CY2019Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	38000000	USD
CY2018Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	38000000	USD
CY2019Q2	mdt	Deferred Tax Liabilities Investment In Subsidiaries DeferredTaxLiabilitiesInvestmentInSubsidiaries	119000000	USD
CY2018Q2	mdt	Deferred Tax Liabilities Investment In Subsidiaries DeferredTaxLiabilitiesInvestmentInSubsidiaries	131000000	USD
CY2019Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1993000000	USD
CY2018Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2078000000	USD
CY2019Q2	us-gaap	Prepaid Taxes PrepaidTaxes	363000000	USD
CY2018Q2	us-gaap	Prepaid Taxes PrepaidTaxes	406000000	USD
CY2019Q2	us-gaap	Income Tax Receivable IncomeTaxReceivable	335000000	USD
CY2018Q2	us-gaap	Income Tax Receivable IncomeTaxReceivable	315000000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	889000000	USD
CY2018Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	704000000	USD
CY2019Q2	mdt	Deferred Tax Assets Netof Valuation Allowance Other DeferredTaxAssetsNetofValuationAllowanceOther	648000000	USD
CY2018Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1423000000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	889000000	USD
CY2018Q2	mdt	Deferred Tax Assets Netof Valuation Allowance Other DeferredTaxAssetsNetofValuationAllowanceOther	662000000	USD
CY2019Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1519000000	USD
CY2018Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1465000000	USD
CY2019Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1278000000	USD
CY2018Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	704000000	USD
CY2019Q2	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	64100000000	USD
CY2018Q2	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	61000000000.0	USD
CY2019Q2	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	178000000	USD
CY2019Q2	mdt	Deferred Tax Assets Tax Credit Carryforwards Not Subjectto Expiration DeferredTaxAssetsTaxCreditCarryforwardsNotSubjecttoExpiration	66000000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6300000000	USD
CY2018Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7200000000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.305
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.009
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.008
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.010
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.012
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.008
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.009
CY2019	mdt	Effective Income Tax Rate Reconciliation Puerto Rico Excise Tax EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax	0.016
CY2018	mdt	Effective Income Tax Rate Reconciliation Puerto Rico Excise Tax EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax	0.011
CY2017	mdt	Effective Income Tax Rate Reconciliation Puerto Rico Excise Tax EffectiveIncomeTaxRateReconciliationPuertoRicoExciseTax	0.015
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.107
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.189
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.279
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.002
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.430
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.010
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.010
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.030
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.010
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	75000000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Acquisition UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition	0	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	-0.038
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.010
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.089
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.044
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0.041
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0.027
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings	0.035
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.105
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.455
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.126
CY2019	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-40000000	USD
CY2019	us-gaap	Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Income Tax Expense Benefit TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit	-30000000	USD
CY2019	us-gaap	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense	42000000	USD
CY2019	mdt	Tax Expense Benefit Associated With Intercompany Legal Entity Restructuring TaxExpenseBenefitAssociatedWithIntercompanyLegalEntityRestructuring	-32000000	USD
CY2019	us-gaap	Income Tax Reconciliation Disposition Of Business IncomeTaxReconciliationDispositionOfBusiness	-20000000	USD
CY2018	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	1900000000	USD
CY2018	us-gaap	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit	2400000000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Restructuring Charges IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges	73000000	USD
CY2018	mdt	Tax Expense Benefit Associated With Saleof Intellectual Property TaxExpenseBenefitAssociatedWithSaleofIntellectualProperty	-579000000	USD
CY2017	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	202000000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Settlements IncomeTaxReconciliationTaxSettlements	404000000	USD
CY2017	us-gaap	Income Tax Reconciliation Disposition Of Business IncomeTaxReconciliationDispositionOfBusiness	125000000	USD
CY2017	mdt	Effective Income Tax Rate Reconciliation Disallowanceof Net Operating Loss Carryforwards EffectiveIncomeTaxRateReconciliationDisallowanceofNetOperatingLossCarryforwards	86000000	USD
CY2017	mdt	Effective Income Tax Rate Reconciliation Tax Settlement Redemptionof Intercompany Noncontrolling Interest Amount EffectiveIncomeTaxRateReconciliationTaxSettlementRedemptionofIntercompanyNoncontrollingInterestAmount	18000000	USD
CY2017	mdt	Effective Income Tax Rate Reconciliation Tax Settlement Redemptionof Intercompany Minority Interest Intercompany Debt Amount EffectiveIncomeTaxRateReconciliationTaxSettlementRedemptionofIntercompanyMinorityInterestIntercompanyDebtAmount	-431000000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Holidays IncomeTaxReconciliationTaxHolidays	437000000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Holidays IncomeTaxReconciliationTaxHolidays	446000000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Holidays IncomeTaxReconciliationTaxHolidays	475000000	USD
CY2019Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1800000000	USD
CY2018Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1700000000	USD
CY2017Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1900000000	USD
CY2018Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1727000000	USD
CY2017Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1896000000	USD
CY2016Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2703000000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	34000000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	13000000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	147000000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	109000000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	63000000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Acquisition UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Acquisition UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition	4000000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	14000000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	120000000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	538000000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	80000000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	467000000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	20000000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	45000000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	28000000	USD
CY2019Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1836000000	USD
CY2018Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1727000000	USD
CY2017Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1896000000	USD
CY2019	mdt	Cash Advance Paidin Connection With Proposed Settlements CashAdvancePaidinConnectionWithProposedSettlements	859000000	USD
CY2018	mdt	Cash Advance Paidin Connection With Proposed Settlements CashAdvancePaidinConnectionWithProposedSettlements	859000000	USD
CY2017	mdt	Cash Advance Paidin Connection With Proposed Settlements CashAdvancePaidinConnectionWithProposedSettlements	0	USD
CY2019Q2	mdt	Unrecognized Tax Benefits Netof Cash Advance Paid UnrecognizedTaxBenefitsNetofCashAdvancePaid	977000000	USD
CY2018Q2	mdt	Unrecognized Tax Benefits Netof Cash Advance Paid UnrecognizedTaxBenefitsNetofCashAdvancePaid	868000000	USD
CY2017Q2	mdt	Unrecognized Tax Benefits Netof Cash Advance Paid UnrecognizedTaxBenefitsNetofCashAdvancePaid	1896000000	USD
CY2019Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1800000000	USD
CY2018Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1700000000	USD
CY2017Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1800000000	USD
CY2019Q2	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	977000000	USD
CY2019Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	172000000	USD
CY2018Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	128000000	USD
CY2017Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	360000000	USD
CY2019	us-gaap	Income Tax Examination Interest Expense IncomeTaxExaminationInterestExpense	48000000	USD
CY2018	us-gaap	Income Tax Examination Interest Expense IncomeTaxExaminationInterestExpense	84000000	USD
CY2017	us-gaap	Income Tax Examination Interest Expense IncomeTaxExaminationInterestExpense	-208000000	USD
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1346400000	shares
CY2018	us-gaap	Net Income Loss NetIncomeLoss	3104000000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	4028000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	4631000000	USD
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1356700000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1378900000	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	7600000	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	7900000	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9000000.0	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	3200000	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	3300000	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	3400000	shares
CY2019	mdt	Incremental Common Shares Attributableto Dilutive Effectof Other Shares IncrementalCommonSharesAttributabletoDilutiveEffectofOtherShares	300000	shares
CY2018	mdt	Incremental Common Shares Attributableto Dilutive Effectof Other Shares IncrementalCommonSharesAttributabletoDilutiveEffectofOtherShares	300000	shares
CY2017	mdt	Incremental Common Shares Attributableto Dilutive Effectof Other Shares IncrementalCommonSharesAttributabletoDilutiveEffectofOtherShares	100000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1357500000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1368200000	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1391400000	shares
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.44
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.29
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.92
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.41
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.27
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.89
CY2019	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	539000000	USD
CY2018	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	552000000	USD
CY2017	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	602000000	USD
CY2019Q2	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-1100000000	USD
CY2018Q2	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-942000000	USD
CY2017	mdt	Defined Contribution Plan Costof Providing Specialand Contractual Termination Benefits DefinedContributionPlanCostofProvidingSpecialandContractualTerminationBenefits	4000000	USD
CY2017	mdt	Defined Benefit Planand Defined Contribution Plan Cash Paymentsand Administrative Fees DefinedBenefitPlanandDefinedContributionPlanCashPaymentsandAdministrativeFees	2000000	USD
CY2019Q2	mdt	Investments Numberof Investments In Processof Liquidation InvestmentsNumberofInvestmentsInProcessofLiquidation	0	fund
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	415000000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	374000000	USD
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	347000000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	216000000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	157000000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	103000000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	61000000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	34000000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	81000000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	652000000	USD
CY2019	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	305000000	USD
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	319000000	USD
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	294000000	USD
CY2019	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Matters</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, income tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. At </span><span style="font-family:inherit;font-size:10pt;">April 26, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">April 27, 2018</span><span style="font-family:inherit;font-size:10pt;">, accrued litigation was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 billion</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">other accrued expenses</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">other liabilities</span><span style="font-family:inherit;font-size:10pt;"> on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Liability Matters</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sprint Fidelis</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2007, a putative class action was filed in the Ontario Superior Court of Justice in Canada seeking damages for personal injuries allegedly related to the Company's Sprint Fidelis family of defibrillation leads. On October 20, 2009, the court certified a class proceeding but denied class certification on plaintiffs' claim for punitive damages. The Company has recognized an expense for probable and estimable damages related to this matter, and during the fourth quarter of fiscal year 2019 the Company paid out previously accrued settlement amounts with no admission of liability, bringing this matter to a conclusion. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">INFUSE Litigation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company estimated law firms representing approximately </span><span style="font-family:inherit;font-size:10pt;"><span>6,000</span></span><span style="font-family:inherit;font-size:10pt;"> claimants asserted or intended to assert personal injury claims against Medtronic in the U.S. state and federal courts involving the INFUSE bone graft product. As of June 1, 2017, the Company </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">had reached agreements to settle substantially all of these claims, and during the fourth quarter of fiscal year 2019 the Company paid out previously accrued settlement amounts with no admission of liability, bringing this matter to a conclusion. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Pelvic Mesh Litigation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. </span><span style="font-family:inherit;font-size:10pt;"><span>Two</span></span><span style="font-family:inherit;font-size:10pt;"> subsidiaries of Covidien supplied pelvic mesh products to </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In fiscal year 2016, Bard paid the Company </span><span style="font-family:inherit;font-size:10pt;"><span>$121 million</span></span><span style="font-family:inherit;font-size:10pt;"> towards the settlement of </span><span style="font-family:inherit;font-size:10pt;"><span>11,000</span></span><span style="font-family:inherit;font-size:10pt;"> of these claims. In May 2017, the agreement with Bard was amended to extend the terms to apply to up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>5,000</span></span><span style="font-family:inherit;font-size:10pt;"> claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately </span><span style="font-family:inherit;font-size:10pt;"><span>15,800</span></span><span style="font-family:inherit;font-size:10pt;"> claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of June 1, 2019, the Company had reached agreements to settle approximately </span><span style="font-family:inherit;font-size:10pt;"><span>15,400</span></span><span style="font-family:inherit;font-size:10pt;"> of these claims. The Company's accrued expenses for this matter are included within accrued litigation as discussed above.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Patent Litigation</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Ethicon</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 14, 2011, Ethicon filed an action against Covidien in the U.S. District Court for the Southern District of Ohio, alleging patent infringement and seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien's favor, and the majority of this ruling was affirmed by the Federal Circuit on August 7, 2015. Following appeal, the case was remanded back to the District Court with respect to </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> patent. On January 21, 2016, Covidien filed a second action in the U.S. District Court for the Southern District of Ohio, seeking a declaration of non-infringement with respect to a second set of patents held by Ethicon. The court consolidated this second action with the remaining patent issues from the first action. Following consolidation of the cases, Ethicon dismissed </span><span style="font-family:inherit;font-size:10pt;"><span>six</span></span><span style="font-family:inherit;font-size:10pt;"> of the asserted patents, leaving a single asserted patent. In addition to claims of non-infringement, the Company asserts an affirmative defense of invalidity. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Sasso</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is involved in litigation in Indiana relating to certain patent and royalty disputes with Dr. Sasso under agreements originally entered into in 1999 and 2001. On November 28, 2018, a jury in Indiana state court returned a verdict against the Company for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$112 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has strong arguments to appeal the verdict and has filed post-trial motions and appeals with the appropriate appellate courts. The Company has not recognized an expense in connection with this matter because it does not currently believe a loss is probable under U.S. GAAP.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Shareholder Related Matters</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Covidien Acquisition</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Merenstein</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Steiner</span><span style="font-family:inherit;font-size:10pt;"> matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On March 20, 2015, the District Court issued an order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal, and, in January of 2016, the Minnesota State Court of Appeals affirmed in part, and reversed in part. On April 19, 2016, the Minnesota Supreme Court granted the Company’s petition to review the issue of whether most of the original claims are properly characterized as direct or derivative under Minnesota law. In August of 2017, the Minnesota Supreme Court affirmed the decision of the Minnesota State Court of Appeals, sending the matter back to the trial court for further proceedings, which are ongoing. The Company has not recognized </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">HeartWare</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 22, 2016, the St. Paul Teachers’ Retirement Fund Association filed a putative class action complaint (the “Complaint”) in the United States District Court for the Southern District of New York against HeartWare on behalf of all persons and entities who purchased or otherwise acquired shares of HeartWare from June 10, 2014 through January 11, 2016 (the “Class Period”). The Complaint was amended on June 29, 2016 and claims HeartWare and one of its executives violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making false and misleading statements about, among other things, HeartWare’s response to a June 2014 U.S. FDA warning letter, the development of the Miniaturized Ventricular Assist Device (MVAD) System and the proposed acquisition of Valtech Cardio Ltd. The Complaint seeks to recover damages on behalf of all purchasers or acquirers of HeartWare’s stock during the Class Period. In August of 2016, the Company acquired HeartWare. In October of 2018, the parties reached an agreement to settle this matter, and in January 2019, the settlement amount was deposited into a qualified settlement fund to be distributed following final court approval. In the fourth quarter of fiscal year 2019, the court approved the settlement, bringing this matter to a conclusion.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Environmental Proceedings</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008, which included a directive to remove a significant volume of soils at the site. After a hearing on the compliance order before the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order, the Maine Board modified the MDEP order and issued a final order requiring removal of </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> landfills, capping of the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> landfills, installation of a groundwater extraction system and long-term monitoring of the site and the </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> remaining landfills.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since the early 2000s, the Company or its predecessors have also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring the Company's predecessor to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following a trial in March 2002, the Court held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that the Company’s predecessor was liable for the cost of performing a study of the River and Bay. Following a second trial in June 2014, the Court ordered that further engineering study and engineering design work was needed to determine the nature and extent of remediation in the Penobscot River and Bay. The Court also appointed an engineering firm to conduct such studies and issue a report on potential remediation alternatives. In connection with these proceedings, reports have been produced including a variety of cost estimates for a variety of potential remedial options. A third trial to determine the course of remediation to be pursued is scheduled to occur in November of 2019.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's accrued expenses for environmental proceedings are included within accrued litigation as discussed above.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Government Matters</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since 2017, the Company has been responding to requests from the Department of Justice and U.S. Department of Health and Human Services for information about business practices relating to a neurovascular product developed and first marketed by ev3 and Covidien. The Company has provided information in response to these requests and is cooperating with the inquiry. The Company has not recognized an expense in connection with any ongoing investigation, because any such potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from the ongoing information requests.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court reviewed this dispute, and on June 9, 2016, issued its opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006. The U.S. Tax Court generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. On April 21, 2017, the IRS filed their Notice of Appeal to the U.S. Court of Appeals for the 8th Circuit regarding the Tax Court Opinion. Oral argument for the Appeal occurred on March 14, 2018. The 8th Circuit Court of Appeals issued their opinion on August 16, 2018, and remanded the case back to the U.S. Tax Court for additional factual findings.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2007 and 2008 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2009, 2010, and 2011 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2012, 2013, and 2014. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed adjustments associated with the utilization of certain net operating losses. The Company disagrees with the IRS and will attempt to resolve these matters at the IRS Appellate level.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medtronic, Inc.’s fiscal years 2015 and 2016 U.S. federal income tax returns are currently being audited by the IRS.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for all tax years through 2012. The statute of limitations for Covidien’s 2013 and 2014 U.S. federal income tax returns lapsed during the first quarter of fiscal years 2018 and 2019, respectively. Covidien's fiscal year 2015 U.S. federal income tax returns are currently being audited by the IRS.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Note </span><span style="font-family:inherit;font-size:10pt;">14</span><span style="font-family:inherit;font-size:10pt;"> for additional discussion of income taxes.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Guarantees</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the acquisition of Covidien, the Company has a guarantee commitment related to certain contingent tax liabilities as a party to the Tax Sharing Agreement that was entered into on June 29, 2007, between Covidien, Tyco International (now Johnson Controls), and Tyco Electronics (now TE Connectivity), associated with the spin-off from Tyco. The Tax Sharing Agreement covers certain income tax liabilities for periods prior to and including the spin-off. Medtronic’s share of the income tax liabilities for these periods is </span><span style="font-family:inherit;font-size:10pt;"><span>42 percent</span></span><span style="font-family:inherit;font-size:10pt;">, with Johnson Controls and TE Connectivity share being </span><span style="font-family:inherit;font-size:10pt;"><span>27 percent</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>31 percent</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. If Johnson Controls and TE Connectivity default on their obligations to the Company under the Tax Sharing Agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties. The most significant amounts at risk under this Tax Sharing Agreement were resolved with the U.S. Tax Court and IRS Appeals resolutions reached in May 2016. However, the Tax Sharing Agreement remains in place with respect to income tax liabilities that are not the subject of such resolution, including certain state and international tax matters that remain open.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to the 2007 separation, including amounts subject to or impacted by the provisions of the Tax Sharing Agreement. The actual amounts that the Company may be required to ultimately accrue or pay under the Tax Sharing Agreement, however, could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">primarily related to tax years that remain open for examination. These balances will also be impacted by the filing of final or amended income tax returns in certain jurisdictions where those returns include a combination of Tyco International, Covidien and/or Tyco Electronics legal entities for periods prior to the 2007 separation.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the Company’s sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal on July 29, 2017, the Company has indemnified Cardinal for certain contingent tax liabilities related to the divested businesses that existed prior to the date of divestiture. The actual amounts that the Company may be required to ultimately accrue or pay could vary depending upon the outcome of the unresolved tax matters.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates’ products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company’s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company’s consolidated earnings, financial position, or cash flows.</span></div>
CY2019Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	500000000	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	5180000000	USD
CY2018Q4	us-gaap	Gross Profit GrossProfit	5278000000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	5281000000	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	5663000000	USD
CY2018Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	900000000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7546000000	USD
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.83
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.95
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.87
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8146000000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7390000000	USD
CY2017Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7050000000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7369000000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8144000000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.75
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7384000000	USD
CY2018Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7481000000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	5038000000	USD
CY2017Q4	us-gaap	Gross Profit GrossProfit	4927000000	USD
CY2018Q1	us-gaap	Gross Profit GrossProfit	5175000000	USD
CY2018Q2	us-gaap	Gross Profit GrossProfit	5746000000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	1077000000	USD
CY2018Q4	us-gaap	Profit Loss ProfitLoss	1120000000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	1271000000	USD
CY2019Q2	us-gaap	Profit Loss ProfitLoss	1182000000	USD
CY2017Q3	us-gaap	Profit Loss ProfitLoss	1009000000	USD
CY2017Q4	us-gaap	Profit Loss ProfitLoss	2013000000	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-1392000000	USD
CY2018Q2	us-gaap	Profit Loss ProfitLoss	1465000000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	1075000000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	1115000000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	1269000000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	1172000000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	1016000000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	2017000000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-1389000000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	1460000000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.79
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.49
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.08
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.82
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.94
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.87
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.74
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.48
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.03
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.07
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	4	segment
CY2019	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	segment
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30557000000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29953000000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29710000000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5197000000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5675000000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	4602000000	USD
CY2019Q2	us-gaap	Assets Assets	89694000000	USD
CY2018Q2	us-gaap	Assets Assets	91393000000	USD
CY2019	us-gaap	Depreciation Depreciation	895000000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5675000000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2580000000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	3095000000	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	19000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	4631000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-975000000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	16000000	USD
CY2018	us-gaap	Depreciation Depreciation	821000000	USD
CY2017	us-gaap	Depreciation Depreciation	937000000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30557000000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29953000000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29710000000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4675000000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4604000000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30557000000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9155000000	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2330000000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10418000000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1764000000	USD
CY2019	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	198000000	USD
CY2019	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	166000000	USD
CY2019	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-258000000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	6268000000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	373000000	USD
CY2019	us-gaap	Interest Expense InterestExpense	1444000000	USD
CY2019	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5197000000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	547000000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	4650000000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3659000000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29953000000	USD
CY2018	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2256000000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9067000000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10238000000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1823000000	USD
CY2018	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	30000000	USD
CY2018	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	61000000	USD
CY2018	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	697000000	USD
CY2018	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-535000000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	6640000000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	181000000	USD
CY2018	us-gaap	Interest Expense InterestExpense	1146000000	USD
CY2018	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9000000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	3104000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1030000000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-9000000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4134000000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29710000000	USD
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9294000000	USD
CY2017	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2193000000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10018000000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1980000000	USD
CY2017	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	303000000	USD
CY2017	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	300000000	USD
CY2017	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-239000000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	5383000000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	313000000	USD
CY2017	us-gaap	Interest Expense InterestExpense	1094000000	USD
CY2017	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	4602000000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	578000000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	4024000000	USD
CY2017	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4000000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	4028000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-744000000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-3000000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3283000000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4393000000	USD
CY2019Q2	us-gaap	Short Term Investments ShortTermInvestments	5455000000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6222000000	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	3753000000	USD
CY2019Q2	mdt	Intercompany Receivable Current IntercompanyReceivableCurrent	0	USD
CY2019Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2144000000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	21967000000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4675000000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	39959000000	USD
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20560000000	USD
CY2019Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1519000000	USD
CY2019Q2	mdt	Investmentin Subsidiaries InvestmentinSubsidiaries	0	USD
CY2019Q2	mdt	Intercompany Receivable Noncurrent IntercompanyReceivableNoncurrent	0	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1014000000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	757000000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	39482000000	USD
CY2019Q2	us-gaap	Assets Assets	89694000000	USD
CY2019Q2	us-gaap	Debt Current DebtCurrent	838000000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1953000000	USD
CY2019Q2	mdt	Intercompany Payable Current IntercompanyPayableCurrent	0	USD
CY2019Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	2189000000	USD
CY2019Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	567000000	USD
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2925000000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8472000000	USD
CY2019Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	24486000000	USD
CY2019Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1651000000	USD
CY2019Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	2838000000	USD
CY2019Q2	mdt	Intercompany Payable Noncurrent IntercompanyPayableNoncurrent	0	USD
CY2019Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1278000000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	50091000000	USD
CY2019Q2	us-gaap	Minority Interest MinorityInterest	121000000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50212000000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89694000000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3669000000	USD
CY2018Q2	us-gaap	Short Term Investments ShortTermInvestments	7558000000	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5987000000	USD
CY2018Q2	us-gaap	Inventory Net InventoryNet	3579000000	USD
CY2018Q2	mdt	Intercompany Receivable Current IntercompanyReceivableCurrent	0	USD
CY2018Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2187000000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	22980000000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4604000000	USD
CY2018Q2	us-gaap	Goodwill Goodwill	39543000000	USD
CY2018Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	21723000000	USD
CY2018Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1465000000	USD
CY2018Q2	mdt	Investmentin Subsidiaries InvestmentinSubsidiaries	0	USD
CY2018Q2	mdt	Intercompany Receivable Noncurrent IntercompanyReceivableNoncurrent	0	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1078000000	USD
CY2018Q2	us-gaap	Assets Assets	91393000000	USD
CY2018Q2	us-gaap	Debt Current DebtCurrent	2058000000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1628000000	USD
CY2018Q2	mdt	Intercompany Payable Current IntercompanyPayableCurrent	0	USD
CY2018Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1988000000	USD
CY2018Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	979000000	USD
CY2018Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3431000000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10084000000	USD
CY2018Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	23699000000	USD
CY2018Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1425000000	USD
CY2018Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	3051000000	USD
CY2018Q2	mdt	Intercompany Payable Noncurrent IntercompanyPayableNoncurrent	0	USD
CY2018Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1423000000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	889000000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	40571000000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	50720000000	USD
CY2018Q2	us-gaap	Minority Interest MinorityInterest	102000000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50822000000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91393000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7007000000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1827000000	USD
CY2018	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	22000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5858000000	USD
CY2018	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	-249000000	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	21000000	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	7370000000	USD
CY2018	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	2494000000	USD
CY2018	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	403000000	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2171000000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1134000000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2532000000	USD
CY2019	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	4683000000	USD
CY2019	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	USD
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-36000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-774000000	USD
CY2019	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	-713000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	7794000000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	7948000000	USD
CY2019	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	2693000000	USD
CY2019	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	992000000	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2877000000	USD
CY2019	mdt	Increase Decreasein Intercompany Payable IncreaseDecreaseinIntercompanyPayable	0	USD
CY2019	mdt	Intercompany Dividends Paid IntercompanyDividendsPaid	0	USD
CY2019	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	14000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5431000000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-78000000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	724000000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3669000000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4393000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4684000000	USD
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	137000000	USD
CY2018	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	6058000000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1068000000	USD
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	3200000000	USD
CY2018	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	4227000000	USD
CY2018	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	USD
CY2018	mdt	Increase Decreasein Intercompany Payable IncreaseDecreaseinIntercompanyPayable	0	USD
CY2018	mdt	Intercompany Dividends Paid IntercompanyDividendsPaid	0	USD
CY2018	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	USD
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-94000000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5197000000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	547000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11954000000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	114000000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1298000000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4967000000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3669000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6880000000	USD
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1324000000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1254000000	USD
CY2017	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	4371000000	USD
CY2017	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	5356000000	USD
CY2017	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	USD
CY2017	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-22000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1571000000	USD
CY2017	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	906000000	USD
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2140000000	USD
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	863000000	USD
CY2017	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	2376000000	USD
CY2017	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	428000000	USD
CY2017	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3544000000	USD
CY2017	mdt	Increase Decreasein Intercompany Payable IncreaseDecreaseinIntercompanyPayable	0	USD
CY2017	mdt	Intercompany Dividends Paid IntercompanyDividendsPaid	0	USD
CY2017	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	USD
CY2017	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	26000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3283000000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65000000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2091000000	USD
CY2016Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2876000000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4967000000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30557000000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9155000000	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2330000000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10418000000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1764000000	USD
CY2019	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	198000000	USD
CY2019	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	166000000	USD
CY2019	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-258000000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	6268000000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	373000000	USD
CY2019	us-gaap	Interest Expense InterestExpense	1444000000	USD
CY2019	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10238000000	USD
CY2017	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	300000000	USD
CY2017	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-239000000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	4650000000	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	19000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	4631000000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-975000000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	16000000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3659000000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29953000000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9067000000	USD
CY2018	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2256000000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1823000000	USD
CY2018	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	30000000	USD
CY2018	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	61000000	USD
CY2018	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	697000000	USD
CY2018	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-535000000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	6640000000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	181000000	USD
CY2018	us-gaap	Interest Expense InterestExpense	1146000000	USD
CY2018	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5675000000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2580000000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	3095000000	USD
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9000000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	3104000000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1030000000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-9000000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4134000000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29710000000	USD
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9294000000	USD
CY2017	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2193000000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10018000000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1980000000	USD
CY2017	mdt	Restructuring Charges Netof Restructuring Reversals RestructuringChargesNetofRestructuringReversals	303000000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	5383000000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	313000000	USD
CY2017	us-gaap	Interest Expense InterestExpense	1094000000	USD
CY2017	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	4602000000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3669000000	USD
CY2018Q2	us-gaap	Short Term Investments ShortTermInvestments	7558000000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3283000000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4393000000	USD
CY2019Q2	us-gaap	Short Term Investments ShortTermInvestments	5455000000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	578000000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	4024000000	USD
CY2017	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4000000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	4028000000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-744000000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-3000000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6222000000	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	3753000000	USD
CY2019Q2	mdt	Intercompany Receivable Current IntercompanyReceivableCurrent	0	USD
CY2019Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2144000000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	21967000000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4675000000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	39959000000	USD
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20560000000	USD
CY2019Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1519000000	USD
CY2019Q2	mdt	Investmentin Subsidiaries InvestmentinSubsidiaries	0	USD
CY2019Q2	mdt	Intercompany Receivable Noncurrent IntercompanyReceivableNoncurrent	0	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1014000000	USD
CY2019Q2	us-gaap	Assets Assets	89694000000	USD
CY2019Q2	us-gaap	Debt Current DebtCurrent	838000000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1953000000	USD
CY2019Q2	mdt	Intercompany Payable Current IntercompanyPayableCurrent	0	USD
CY2019Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	2189000000	USD
CY2019Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	567000000	USD
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2925000000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8472000000	USD
CY2019Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	24486000000	USD
CY2019Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1651000000	USD
CY2019Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	2838000000	USD
CY2019Q2	mdt	Intercompany Payable Noncurrent IntercompanyPayableNoncurrent	0	USD
CY2019Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1278000000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	757000000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	39482000000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	50091000000	USD
CY2019Q2	us-gaap	Minority Interest MinorityInterest	121000000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50212000000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89694000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7007000000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1827000000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	22980000000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4604000000	USD
CY2018Q2	us-gaap	Goodwill Goodwill	39543000000	USD
CY2018Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	21723000000	USD
CY2018Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1465000000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1134000000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2532000000	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5987000000	USD
CY2018Q2	us-gaap	Inventory Net InventoryNet	3579000000	USD
CY2018Q2	mdt	Intercompany Receivable Current IntercompanyReceivableCurrent	0	USD
CY2018Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2187000000	USD
CY2018Q2	mdt	Investmentin Subsidiaries InvestmentinSubsidiaries	0	USD
CY2018Q2	mdt	Intercompany Receivable Noncurrent IntercompanyReceivableNoncurrent	0	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1078000000	USD
CY2018Q2	us-gaap	Assets Assets	91393000000	USD
CY2018Q2	us-gaap	Debt Current DebtCurrent	2058000000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1628000000	USD
CY2018Q2	mdt	Intercompany Payable Current IntercompanyPayableCurrent	0	USD
CY2018Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1988000000	USD
CY2018Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	979000000	USD
CY2018Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3431000000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10084000000	USD
CY2018Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	23699000000	USD
CY2018Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1425000000	USD
CY2018Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	3051000000	USD
CY2018Q2	mdt	Intercompany Payable Noncurrent IntercompanyPayableNoncurrent	0	USD
CY2018Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1423000000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	889000000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	40571000000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	50720000000	USD
CY2018Q2	us-gaap	Minority Interest MinorityInterest	102000000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50822000000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91393000000	USD
CY2019	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	4683000000	USD
CY2019	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	USD
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-36000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-774000000	USD
CY2019	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	-713000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	7794000000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	7948000000	USD
CY2019	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	2693000000	USD
CY2019	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	992000000	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2877000000	USD
CY2019	mdt	Increase Decreasein Intercompany Payable IncreaseDecreaseinIntercompanyPayable	0	USD
CY2019	mdt	Intercompany Dividends Paid IntercompanyDividendsPaid	0	USD
CY2019	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	14000000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5431000000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-78000000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	724000000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3669000000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4393000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4684000000	USD
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	137000000	USD
CY2018	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	6058000000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1068000000	USD
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	3200000000	USD
CY2018	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	4227000000	USD
CY2018	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	USD
CY2018	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	22000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5858000000	USD
CY2018	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	-249000000	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	21000000	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	7370000000	USD
CY2018	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	2494000000	USD
CY2018	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	403000000	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2171000000	USD
CY2018	mdt	Increase Decreasein Intercompany Payable IncreaseDecreaseinIntercompanyPayable	0	USD
CY2018	mdt	Intercompany Dividends Paid IntercompanyDividendsPaid	0	USD
CY2018	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	USD
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-94000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11954000000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	114000000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1298000000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4967000000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3669000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6880000000	USD
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1324000000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1254000000	USD
CY2017	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	4371000000	USD
CY2017	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	5356000000	USD
CY2017	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	USD
CY2017	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-22000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1571000000	USD
CY2017	us-gaap	Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess	906000000	USD
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2140000000	USD
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	863000000	USD
CY2017	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	2376000000	USD
CY2017	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	428000000	USD
CY2017	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3544000000	USD
CY2017	mdt	Increase Decreasein Intercompany Payable IncreaseDecreaseinIntercompanyPayable	0	USD
CY2017	mdt	Intercompany Dividends Paid IntercompanyDividendsPaid	0	USD
CY2017	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	USD
CY2017	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	26000000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3283000000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65000000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2091000000	USD
CY2016Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2876000000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4967000000	USD

Files In Submission

Name	View Source	Status
0001613103-19-000028-index-headers.html	Edgar Link	pending
0001613103-19-000028-index.html	Edgar Link	pending
0001613103-19-000028.txt	Edgar Link	pending
0001613103-19-000028-xbrl.zip	Edgar Link	pending
chart-d00f0b7d74c05ebcaf8.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mdt-20190331.xsd	Edgar Link	pending
mdt-20190331_cal.xml	Edgar Link	unprocessable
mdt-20190331_def.xml	Edgar Link	unprocessable
mdt-20190331_lab.xml	Edgar Link	unprocessable
mdt-20190331_pre.xml	Edgar Link	unprocessable
mdt-20190426xex21.htm	Edgar Link	pending
mdt-20190426xex23.htm	Edgar Link	pending
mdt-20190426xex24.htm	Edgar Link	pending
mdt-20190426xex311.htm	Edgar Link	pending
mdt-20190426xex312.htm	Edgar Link	pending
mdt-20190426xex321.htm	Edgar Link	pending
mdt-20190426xex322.htm	Edgar Link	pending
mdt-20190426xex424.htm	Edgar Link	pending
mdt-2019426x10k.htm	Edgar Link	pending
mdt-2019426x10k_htm.xml	Edgar Link	completed
mdtlogo2a83.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
operationsbymarketfy19v2a03.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDT
Medtronic plc Stock $mdt

2019 Q2 Form 10-K Financial Statement

#000161310319000028 Filed on June 21, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDT Medtronic plc Stock $mdt

2019 Q2 Form 10-K Financial Statement

#000161310319000028 Filed on June 21, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDT
Medtronic plc Stock $mdt